Cystic fibrosis news shared on CFRI’s social media pages related to CF research, education, advocacy, patient wellness support and more!

MAY, 2021

NEW CRISPR TECHNOLOGY OFFERS CONTROL OF EPIGENETIC INHERITANCE

SOCIAL DISTANCING INSIDE CAN PROVIDE A FALSE SENSE OF SECURITY

MANY WHO TEST POSITIVE FOR COVID-19 BUT DO NOT REQUIRE HOSPITAL CARE SEEK MEDICAL CARE IN FOLLOWING MONTHS

KB407 GENE THERAPY FOUND SAFE IN ANIMALS, IN-HUMAN TRIAL EXPECTED LATER THIS YEAR

CDC SAYS FULLY VACCINATED AMERICANS CAN NOW GO OUTSIDE WITHOUT A MASK

CPAP THERAPY MAY AFFECT BMI IN ADULTS WITH OSA, STUDY INDICATES

MANY PEOPLE STILL PREFER CONVENIENCE OF JOHNSON AND JOHNSON ONE-DOSE COVID-19 VACCINE

FDA PROMISES TO ISSUE NEW RULES WITHIN A YEAR BANNING MENTHOL IN TOBACCO PRODUCTS

OP-ED: ANTIBIOTIC RESISTANCE, CHRONIC DISEASE AND COVID-19 – A TRIPLE THREAT

APRIL, 2021

SWEAT-MEASURING STICKER MAY AID CF DIAGNOSIS IN CHILDREN

LEAVING MIDDLE SEATS ON AIRPLANES VACANT MAY REDUCE RISK OF CORONAVIRUS EXPOSURE

RISK OF BRAIN BLOOD CLOTS IS HIGHER FROM COVID-19 INFECTION THAN FROM COVID-19 VACCINES

EXPERTS CONCERNED ABOUT IMPACT OF J&J CORONAVIRUS VACCINE PAUSE

FREE ONLINE CLASSES FOR THE CF COMMUNITY AT STROLO UNIVERSITY

CFRI JOINS 80 NATIONAL PATIENT GROUPS IN AN OPEN LETTER CALLING ON LAWMAKERS TO REJECT HEALTH POLICIES THAT DISCRIMINATE

OPTION 2 TRIAL TESTING MS1819 FOR EPI POSTS ‘MIXED’ TOPLINE RESULTS

RESPINOVA’S PULSEHALER DEVICE RECEIVES FDA APPROVAL

PHASE 2 TRIAL ADVANCING: BX004, PHAGE THERAPY FOR BACTERIAL INFECTIONS

RACIAL BIAS IN PULSE OXIMETRY MEASUREMENTS

APRIL 24TH IS TAKE BACK DAY – AN IMPORTANT REMINDER TO SAFELY DISPOSE OF UNUSED MEDICATION

CDC: HALF OF ALL US ADULTS HAVE RECEIVED AT LEAST ONE COVID-19 VACCINE DOSE

MARCH, 2021

FEBRUARY, 2021

OP-ED: SB 5020 INCLUDES GROUP KNOWN FOR DISCRIMINATORY PRACTICES

ASTRAZENECA VACCINE APPEARS TO SUBSTANTIALLY REDUCE TRANSMISSION OF THE CORONAVIRUS

FDA TO REVIEW TRIKAFTA FOR PATIENTS AS YOUNG AS SIX YEARS

KINNEAR PHARMACEUTICALS TO RECEIVE UP TO $3M TO FOR DEVELOPMENT OF ANTI-INFECTIVE FROM CF FOUNDATION

TRANSMISSION AND ANTIBIOTIC RESISTANCE OF ACHROMOBACHTER BACTERIA IN CYSTIC FIBROSIS

JANUARY, 2021

AzurRx STARTS DOSING FIRST CF PATIENTS IN STUDY OF LIPASE ENZYME MS1819

MINORITIES IN US OFTEN INELIGIBLE FOR CFTR MODULATORS DUE TO POORLY STUDIED MUTATIONS

UPDATE: WASHINGTON STATE SENATE HEALTH AND LONG TERM CARE COMMITTEE HEARS TESTIMONY ON SB 5020: “Rx DRUG PRICE INCREASES”